MelliCell

MelliCell is a biotechnology company developing fat-targeted therapeutics for obesity and related chronic diseases. Powered by its proprietary M3 technology, it generates mature human adipose tissue in vitro to illuminate adipocyte biology and enable drug discovery, tissue engineering, and regenerative applications. The pipeline includes MCL5008, an oral, once-daily obesity therapy candidate designed to eliminate obesity without muscle loss, taking a fat-cell-directed approach distinct from GLP-1 drugs.